◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › A › ARCT

Arcturus Therapeutics Holdings Inc (ARCT) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-10-03

Arcturus Therapeutics Holdings Inc (ARCT) operates in the BIOTECHNOLOGY industry and is headquartered in San Diego, United States with about 106 employees. Its market capitalization is roughly $314 million. In the fiscal year ended 2025-12-31, ARCT reported $67M in revenue and ($66M) in net income.

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system.

Interactive charts & full statements → Open the ARCT valuation workbench →

ARCT Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Revenue	$24M	$67M	$138M	$158M	$206M	$12M	$10M	$21M	$16M	$13M	$20M	$6M	$0M	$0M	—	—
Gross Profit	$20M	$64M	$138M	$158M	$206M	$12M	($46M)	$21M	($1M)	$13M	$20M	$6M	$0M	$0M	—	—
Gross Margin %	83.2%	95.5%	100.0%	100.0%	100.0%	100.0%	-486.5%	100.0%	-7.8%	96.9%	98.6%	99.2%	—	—	—	—
Operating Income (EBIT)	($103M)	($75M)	($96M)	($78M)	$12M	($203M)	($72M)	($26M)	($22M)	($10M)	($25M)	($20M)	($33M)	($10M)	($2M)	($4M)
Operating Margin %	-433.4%	-111.5%	-69.1%	-49.6%	5.9%	-1641.3%	-749.8%	-122.7%	-138.5%	-80.7%	-123.5%	-320.9%	—	—	—	—
Net Income	($93M)	($66M)	($81M)	($30M)	$9M	($204M)	($72M)	($26M)	($22M)	($11M)	($25M)	($19M)	($33M)	($11M)	($2M)	($4M)
Net Margin %	-391.9%	-97.9%	-58.5%	-18.8%	4.5%	-1648.0%	-756.4%	-125.0%	-138.3%	-83.9%	-120.7%	-316.9%	—	—	—	—
EBITDA	($83M)	($63M)	($77M)	($24M)	$15M	($200M)	($71M)	($24M)	($21M)	($10M)	($1M)	($2M)	($33M)	($10M)	($2M)	($4M)
Earnings Per Share (EPS)	$-3.34	$-2.40	$-3.00	$-1.12	$0.35	$-7.74	$-3.55	$-2.15	$-2.16	$-3.53	$-6.25	$-6.29	$-16.81	$-11.00	$-0.99	$-2.47
Shares Outstanding (M)	28M	27M	27M	27M	27M	26M	20M	12M	10M	3M	4M	3M	2M	1M	2M	2M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ARCT Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$3M	$1M	$3M	$17M	$25M	$29M	$21M	$39M
Gross Profit	$3M	$0M	$3M	$14M	$25M	$29M	$21M	$39M
Gross Margin %	100.0%	-7.9%	100.0%	80.5%	100.0%	100.0%	100.0%	100.0%
Operating Income (EBIT)	($26M)	($30M)	($31M)	($17M)	($12M)	($17M)	($33M)	($11M)
Operating Margin %	-863.3%	-4882.0%	-1016.1%	-96.3%	-47.4%	-57.3%	-159.0%	-27.7%
Net Income	($24M)	($27M)	($29M)	($13M)	($9M)	($14M)	($30M)	($7M)
Net Margin %	-803.8%	-4420.3%	-943.8%	-78.4%	-37.5%	-47.9%	-142.9%	-17.8%
EBITDA	($24M)	($26M)	($20M)	($13M)	($8M)	($13M)	($29M)	($6M)
Earnings Per Share (EPS)	$-0.84	$-0.95	$-1.06	$-0.49	$-0.34	$-0.52	$-1.11	$-0.26
Shares Outstanding (M)	28M	28M	27M	27M	27M	27M	27M	27M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ARCT Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Cash from Operations (CFO)	($73M)	($74M)	($60M)	($18M)	$32M	($135M)	($43M)	($6M)	($21M)	$0M	($19M)	($18M)	($28M)	($7M)	($2M)	($2M)
Capital Expenditures (CapEx)	$0M	$0M	$1M	$3M	$8M	$3M	$2M	$1M	$1M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($73M)	($75M)	($60M)	($21M)	$24M	($138M)	($45M)	($7M)	($22M)	($1M)	($19M)	($18M)	($28M)	($7M)	($2M)	($2M)
FCF Margin %	-306.9%	-110.8%	-43.6%	-13.3%	11.8%	-1120.2%	-467.6%	-34.9%	-141.2%	-5.5%	-94.8%	-298.6%	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ARCT Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($20M)	($19M)	($16M)	($17M)	($6M)	($35M)	$0M	($24M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($20M)	($19M)	($16M)	($17M)	($6M)	($35M)	$0M	($24M)
FCF Margin %	-672.9%	-3187.1%	-531.1%	-101.1%	-23.5%	-120.1%	-1.4%	-61.4%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ARCT Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31
Total Assets	$224M	$271M	$344M	$429M	$450M	$393M	$476M	$82M	$44M	$52M	$52M	$72M	$22M	$50M	$0M	$1M
Cash & Cash Equivalents	$191M	$231M	$237M	$292M	$392M	$370M	$463M	$71M	$37M	$25M	$2M	$17M	$2M	$22M	$0M	$0M
Total Liabilities	$53M	$57M	$103M	$151M	$180M	$165M	$80M	$56M	$31M	$18M	$4M	$2M	$2M	$2M	$1M	$0M
Total Debt (Short + Long-Term)	$4M	$4M	$4M	$4M	$65M	$65M	$17M	$16M	$10M	$0M	$0M	$0M	$0M	$0M	$1M	$0M
Total Shareholders' Equity	$172M	$214M	$241M	$279M	$270M	$228M	$397M	$26M	$14M	$34M	$47M	$69M	$20M	$49M	($1M)	$1M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ARCT viewer.

Other Companies in BIOTECHNOLOGY

FENC · Fennec Pharmaceuticals Inc — $359 million
KYTX · Kyverna Therapeutics, Inc. Common Stock — $351 million
SPRY · ARS Pharmaceuticals, Inc — $336 million
AVIR · Atea Pharmaceuticals Inc — $330 million
ENTA · Enanta Pharmaceuticals Inc — $312 million
PRLD · Prelude Therapeutics Inc — $309 million
BNTC · Benitec Biopharma Inc. — $305 million
VOGX · Vogenx Inc Common Stock — $301 million

← ARCP All “A” companies ARCX →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.